Qiagen

QGEN

Market cap $9.92B

Overview Fund Activity

45.74 USD

+0.32

0.7%

At close Updated Sep 18, 4:00 PM EDT

Pre-market

After hours

45.74

0.00

0%

1 day

0.7%

5 days

-0.52%

1 month

-5.98%

3 months

-1.74%

6 months

15.07%

Year to date

-0.11%

1 year

-2.66%

5 years

-14.73%

10 years

51.06%

About: Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).

Employees: 5,700

Healthcare Diagnostics & Research

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

84% more call options, than puts

Call options by funds: $50.2M | Put options by funds: $27.3M

60% more first-time investments, than exits

New positions opened: 64 | Existing positions closed: 40

25% more capital invested

Capital invested by funds: $5.78B [Q1] → $7.23B (+$1.45B) [Q2]

20% more repeat investments, than reductions

Existing positions increased: 121 | Existing positions reduced: 101

7% more funds holding

Funds holding: 296 [Q1] → 316 (+20) [Q2]

3.21% more ownership

Funds ownership: 66.31% [Q1] → 69.52% (+3.21%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 4 [Q1] → 4 (+0) [Q2]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$50

9% upside

Avg. target

$53

15% upside

High target

$55

20% upside

3 analyst ratings

2 positive

67%

1 neutral

33%

0 negative

0%

UBS John Sourbeer	$50	Neutral Maintained	7 Aug 2025
B of A Securities Derik De Bruin	$53	Buy Maintained	26 Jun 2025
Barclays Luke Sergott	$55	Overweight Initiated	24 Jun 2025

See Analyst Rankings

Financial journalist opinion

Based on 10 articles about QGEN published over the past 30 days

Zacks Investment Research

QGEN Stock Gains From CE-IVDR Certification for QIAstat-Dx Portfolio

QIAGEN secures CE-IVDR certification for its full QIAstat-Dx portfolio, boosting its diagnostics arm and lifting shares.

QGEN Stock Gains From CE-IVDR Certification for QIAstat-Dx Portfolio

QIAGEN Secures European CE-IVDR Certification for Full QIAstat-Dx Portfolio

VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has achieved CE-IVDR certification for its full portfolio of QIAstat-Dx syndromic testing systems and panels, including an expanded Meningitis/Encephalitis (ME) Panel that sets a new benchmark in the diagnosis of central nervous system (CNS) infections. The QIAstat-Dx system now offers CE-IVDR certified panels for respiratory, gastrointestinal and CNS infections that help clinicians d.

QIAGEN Secures European CE-IVDR Certification for Full QIAstat-Dx Portfolio

Qiagen N.V. (QGEN) Presents At Baird Global Healthcare Conference 2025 Prepared Remarks Transcript

Qiagen N.V. (NYSE:QGEN ) Baird Global Healthcare Conference 2025 September 10, 2025 1:25 PM EDT Company Participants Roland Sackers - CFO, MD & Member of Management Board John Gilardi - VP & Head of Corporate Communications Presentation Unknown Analyst Diagnostics here at Baird.

Qiagen N.V. (QGEN) Presents At Baird Global Healthcare Conference 2025 Prepared Remarks Transcript

Qiagen N.V. (QGEN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Qiagen N.V. (NYSE:QGEN ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 1:05 PM EDT Company Participants Roland Sackers - CFO, MD & Member of Management Board John Gilardi - VP & Head of Corporate Communications Conference Call Participants Aisyah Noor - Morgan Stanley, Research Division Presentation Aisyah Noor Equity Analyst So thanks for joining us today.

Qiagen N.V. (QGEN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Zacks Investment Research

QIAGEN Stock May Benefit From the US Clearance of QIAstat-Dx Rise

QGEN announces the launch of FDA-cleared QIAstat-Dx Rise, which may boost U.S. diagnostic access and testing capacity worldwide.

QIAGEN Stock May Benefit From the US Clearance of QIAstat-Dx Rise

QIAGEN Gains U.S. Clearance of Higher-Throughput QIAstat-Dx Rise, Expanding Patient Access to Rapid Syndromic Testing

GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of QIAstat‑Dx Rise – a version of the QIAstat-Dx automated syndromic testing system that offers unparalled throughput with the easiest workflow available to customers worldwide. The new system, which received clearance from the U.S. Food and Drug Administration (FDA), is designed to meet the needs of hospitals and reference laboratories seeking highly automat.

QIAGEN Gains U.S. Clearance of Higher-Throughput QIAstat-Dx Rise, Expanding Patient Access to Rapid Syndromic Testing

QIAGEN N.V. Announces Conversion Price of New Net Share Settled Convertible Bonds

VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. NOT FOR DISTRIBUTION TO ANY U.S. PERSON. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS PRESS RELEASE. QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) ("QIAGEN" or the "Company") announces the final terms of the new senior, unsecur.

QIAGEN N.V. Announces Conversion Price of New Net Share Settled Convertible Bonds

QIAGEN N.V. Announces Successful Placement of New Net Share Settled Convertible Bonds

VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. NOT FOR DISTRIBUTION TO ANY U.S. PERSON. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS PRESS RELEASE. QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) ("QIAGEN") announces certain terms of the new senior, unsecured net share settle.

QIAGEN N.V. Announces Successful Placement of New Net Share Settled Convertible Bonds

QIAGEN N.V. Launches Non-US Offering of Net Share Settled Convertible Bonds

VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. NOT FOR DISTRIBUTION TO ANY U.S. PERSON. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS PRESS RELEASE. The Managing Board and Supervisory Board of QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) ("QIAGEN" or the "Company") have res.

QIAGEN N.V. Launches Non-US Offering of Net Share Settled Convertible Bonds

Qiagen: Diagnostics Vs. Life Sciences Pair Trade Analysis

Diagnostics now outperform Life Sciences due to academic funding cuts, making Qiagen's defensive profile more attractive in the current market. Qiagen offers stable growth, high profitability, and low leverage, providing a resilient investment option amid sector volatility and macroeconomic uncertainty. While Qiagen is a strong short-term buy, investors should also consider peers like SysMex, BioMerieux, and CellaVision for diversification and growth potential.

Qiagen: Diagnostics Vs. Life Sciences Pair Trade Analysis

See News Rankings

Charts implemented using Lightweight Charts™